Cagrilintide + Semaglutide 10 mg Blend

Metabolic & weight Investigational (in clinical trials)

Amylin analog + GLP-1 receptor agonist blend · also known as CagriSema, Cagrilintide/Semaglutide

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

This 10 mg vial holds 5 mg each of cagrilintide and semaglutide. The pairing follows the combination that has been studied in registered trials for weight management and type 2 diabetes, where both agents are escalated together in equal amounts. Escalation in published schedules is stepwise rather than starting at the target.

Commonly reported dosing (10 mg vial)

Reconstituted with 3 mL → 3.333 mg/mL.

Phase	Dose	Volume	U-100 units
Starting Weeks 1-4, total blend (about 0.25 mg of each peptide)	500 mcg	0.15 mL	15
Standard Weeks 9-12, total blend (about 1 mg of each)	2 mg	0.6 mL	60

Each 500 mcg draw contains 250 mcg Cagrilintide + 250 mcg Semaglutide.

Frequency: Once weekly, subcutaneous · Half-life: Long (weekly dosing for both peptides)

Open in calculator

Commonly reported dose escalation

Weeks	Dose	Volume	U-100 units
Weeks 1-4	500 mcg	0.15 mL	15
Weeks 5-8	1 mg	0.3 mL	30
Weeks 9-12	2 mg	0.6 mL	60
Weeks 13-16	3.4 mg	1.02 mL	102 (warning)
Week 17+	4.8 mg	1.44 mL	144 (warning)

⚠ More than the vial contains or more than a 1 mL syringe holds at this concentration — a larger vial or different reconstitution would be needed.

Higher steps may need a larger vial or more than one draw. Escalation schedules vary; dosing decisions belong to a licensed clinician.

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 10 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 3.33 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Sealed vials are commonly stored refrigerated (2-8 °C) and protected from light, or frozen for long-term storage.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and not frozen.

Commonly used within 28 days of mixing.

How it works

Semaglutide activates GLP-1 receptors, supporting glucose-dependent insulin release, slower gastric emptying and reduced appetite. Cagrilintide mimics amylin, a pancreatic hormone, and engages satiety circuits through a separate receptor family, so the pair is studied as complementary.

Researched for

Studied in clinical trials of co-administered cagrilintide and semaglutide for weight management and type 2 diabetes.
Investigated for additive satiety effects compared with either agent alone.

Notes

Because it is a blend, each weekly amount covers both peptides together; chart figures split it equally.
Gastrointestinal effects such as nausea are the most commonly reported early adverse events in trials, and they track the escalation schedule.
Semaglutide is FDA-approved as single-agent products; cagrilintide and the fixed combination are investigational in the US.
Approved semaglutide products are pre-filled pens and no combined product is approved; the reconstitution figures here apply to research vials.
The top step (4.8 mg total, about 2.4 mg of each) is about 1.44 mL at 3 mL reconstitution, beyond a 1 mL syringe; it appears in the escalation table only.